Ranji, Parmida
Jonasson, Emma
Andersson, Lisa
Filges, Stefan
Luna Santamaría, Manuel
Vannas, Christoffer
Dolatabadi, Soheila
Gustafsson, Anna
Myklebost, Ola
Håkansson, Joakim
Fagman, Henrik
Landberg, Göran
Åman, Pierre
Ståhlberg, Anders http://orcid.org/0000-0003-4243-0191
Funding for this research was provided by:
Stiftelsen Assar Gabrielssons Fond
Johan Jansson Foundation
Västra Götalandsregionen
Cancerfonden (2022-2080)
Barncancerfonden (2022-0030)
Vetenskapsrådet (2021-01008)
the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (965065)
VINNOVA (2017-03737)
Sjöbergstiftelsen
Stiftelserna Wilhelm och Martina Lundgrens
University of Gothenburg
Article History
Received: 10 January 2024
Accepted: 16 April 2024
First Online: 26 April 2024
Declarations
:
: All in vivo experiments were approved by the Regional animal ethics committee of Gothenburg, Sweden (129-2016 and 5.8.18-23035/2021). The use of patient material for research, including the generation of tumor models, was approved by the Committee for Medical Ethics in South-Eastern Norway, project 17866.
: Not applicable.
: AS and GL are co-inventors of the patient-derived scaffold approach that is patent approved (EP3535421/US11840732). AS is board member and declares stock ownership in Tulebovaasta, Iscaff Pharma and SiMSen Diagnostics. GL is board member and declares stock ownership in Iscaff Pharma and Sortina Pharma.